Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer (LUMINANCE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04774380 |
|
Recruitment Status :
Recruiting
First Posted : March 1, 2021
Last Update Posted : February 24, 2022
|
Sponsor:
AstraZeneca
Information provided by (Responsible Party):
AstraZeneca
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
Study to determine the safety and tolerability profile of durvalumab with platinum (cisplatin or carboplatin) plus etoposide (EP) as first-line treatment in participants with extensive-stage small-cell lung cancer.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Extensive-stage Small Cell Lung Cancer | Drug: Durvalumab Drug: Cisplatin Drug: Carboplatin Drug: Etoposide | Phase 3 |
The study will be conducted in North America, Europe and Turkey.
In this single arm study participants will be treated with with durvalumab alone and concurrently with platinum-based chemotherapy and etoposide during the study period until radiological disease progression, unless there is clinical progression, unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met, as per investigator assessment.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 150 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase IIIb, Single-arm, Multi-center, International Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer (LUMINANCE) |
| Actual Study Start Date : | November 11, 2021 |
| Estimated Primary Completion Date : | June 21, 2023 |
| Estimated Study Completion Date : | March 28, 2024 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Lung cancer
MedlinePlus related topics:
Lung Cancer
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Durvalumab - (cisplatin or carboplatin) - Etoposide
Participants will receive durvalumab dose A administered via intravenous (IV) infusion concurrently with platinum-based chemotherapy and etoposide every 3 weeks (q3w). Thereafter, durvalumab monotherapy will be continued every 4 weeks post-chemotherapy unless specific treatment discontinuation criteria are met.
|
Drug: Durvalumab
Participants will receive durvalumab via IV infusion on Day 1 of each cycle. Drug: Cisplatin Participants will receive cisplatin via IV administration on Day 1 of each cycle. Drug: Carboplatin Participants will receive carboplatin via IV administration Day 1 of each cycle. Drug: Etoposide Participants will receive etoposide via IV administration on days 1 to 3 of each cycle. |
Primary Outcome Measures :
- Number of participants with incidence of Grade 3 and higher adverse events (AEs) [ Time Frame: Until disease progression (Approximately upto 1.6 Years) ]Assessment of incidence of Grade 3 and higher adverse events to evaluate safety and tolerability profile of durvalumab + EP treatment.
- Number of participants with incidence of Immune mediated adverse events (imAEs) [ Time Frame: Until disease progression (Approximately upto 1.6 Years) ]Assessment of imAEs to evaluate safety and tolerability profile of durvalumab + EP treatment.
Secondary Outcome Measures :
- Progression-free survival (PFS) [ Time Frame: From screening until disease progression (Approximately 2 Years) ]Assessment of efficacy of durvalumab + EP treatment by evaluating PFS according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). The PFS is the time from the first date of treatment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdraws from Investigational medicinal product (IMP) or receives another anticancer therapy prior to progression.
- Objective response rate (ORR) [ Time Frame: From screening until disease progression (Approximately 2 Years) ]Assessment of the efficacy of durvalumab + EP treatment by evaluating ORR according to RECIST 1.1. The ORR will be assessed based on Investigator-assessed response to treatment of complete response (CR) and partial response (PR), per RECIST1.1.
- Duration of response (DoR) [ Time Frame: From screening until disease progression (Approximately 2 Years) ]Assessment of the efficacy of durvalumab + EP treatment by evaluating DoR according to RECIST 1.1. The DoR is time from the date of first documented response per RECIST1.1 until the first date of documented progression per RECIST1.1 or death in the absence of disease progression.
- Percentage of participants remaining in response, 12 months from the time of first documented objective response (DoR12) [ Time Frame: From screening until disease progression (Approximately 2 Years) ]Assessment of the efficacy of durvalumab + EP treatment by evaluating DoR12 according to RECIST 1.1.
- Percentage of participants alive and progression-free at 12 months from first date of treatment (PFS12) [ Time Frame: From screening until disease progression (Approximately 2 Years) ]Assessment of the efficacy of durvalumab + EP treatment by evaluating PFS12 according to RECIST 1.1.
- Overall (OS) [ Time Frame: From screening until death due to any cause (Approximately 2 Years) ]Assessment of the efficacy of durvalumab + EP treatment by evaluating OS according to RECIST 1.1. The OS is the time from the first date of treatment until death due to any cause.
- Percentage of participants alive at 12 months from first date of treatment (OS12) [ Time Frame: From screening until disease progression (Approximately 2 Years) ]Assessment of the efficacy of durvalumab + EP treatment by evaluating OS12 according to RECIST 1.1.
- Number of participants with adverse events and serious adverse events [ Time Frame: From Cycle 1 (3 weeks [21 days]) until disease progression (Approximately 2 Years) ]Assessment of adverse events and serious adverse events to evaluate safety and tolerability profile of durvalumab + EP treatment.
- Number of participants with adverse events of special interests [ Time Frame: From Cycle 1 (3 weeks [21 days]) until disease progression (Approximately 2 Years) ]Assessment of adverse events of special interests to evaluate safety and tolerability profile of durvalumab + EP treatment.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 130 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Histologically- or cytologically-documented ES-SCLC (stage IV [T any, N any, M1 a/b], or with T3-4 due to multiple lung nodules that are too extensive or have tumor/nodal volume that is too large to be encompassed in a tolerable radiation plan (Brain metastases; must be asymptomatic or treated and stable off steroids and anticonvulsants for at least 1 month prior to study treatment)
- Participants must be considered suitable to receive a platinum-based chemotherapy regimen as 1st line treatment for the ES-SCLC. Chemotherapy must contain either cisplatin or carboplatin in combination with etoposide
- World Health Organization/ Eastern Cooperative Oncology Group performance status of 0 to 2 at enrollment Baseline computed tomography/ magnetic resonance imaging results of the brain, chest and abdomen (including liver and adrenal glands) within 28 days prior to the treatment initiation
- No prior exposure to immune-mediated therapy including, but not limited to, other anti- CTLA-4, anti-Programmed cell death-1 (PD-1), anti- Programmed cell death ligand-1 (PD-L1), and anti-PD-L2 (anti-PD-L2) antibodies, excluding therapeutic anticancer vaccines
- Adequate organ and marrow function
- Body weight > 30 kg
- Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal participants
Exclusion Criteria:
- History of allogeneic organ transplantation
- Active or prior documented autoimmune or inflammatory disorders, systemic lupus erythematosus, sarcoidosis syndrome, or wegener syndrome
- Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, uncontrolled cardiac arrhythmia, active interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the participant to give written informed consent
-
History of another primary malignancy except for:
- Malignancy treated with curative intent and with no known active disease ≥ 5 years before the first dose of Investigational medicinal product (IMP) and of low potential risk for recurrence
- Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
- Adequately treated carcinoma in situ without evidence of disease
- History of leptomeningeal carcinomatosis and active primary immunodeficiency
- Active infection including tuberculosis, hepatitis B, hepatitis C, human immunodeficiency virus
- Any unresolved toxicity Common Terminology Criteria for Adverse Events Grade ≥ 2 from previous anticancer therapy
- Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients
- Received prior systemic therapy for ES-SCLC
- Medical contraindication to platinum (cisplatin or carboplatin)-etoposide-based chemotherapy
- Any concurrent chemotherapy, IMP, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions is acceptable
- Planned consolidation chest radiation therapy. Radiation therapy outside of the chest for palliative care is allowed but must be completed before first dose of the study medication
- Receipt of live attenuated vaccine within 30 days prior to the first dose of in IMP
- Major surgical procedure within 28 days prior to the first dose of IMP
- Participants who have received prior immunotherapy agents including anti-PD-1 or anti PD-L1
- Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab
- Participation in another clinical study with an investigational product administered in the last 4 weeks
- Female participants who are pregnant or breastfeeding or male or female participants of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab and 180 days after the last dose of etoposide
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04774380
Contacts
| Contact: AstraZeneca Clinical Study Information Center | 1-877-240-9479 | information.center@astrazeneca.com |
Locations
Show 60 study locations
Sponsors and Collaborators
AstraZeneca
| Responsible Party: | AstraZeneca |
| ClinicalTrials.gov Identifier: | NCT04774380 |
| Other Study ID Numbers: |
D419QC00007 2020-005537-32 ( EudraCT Number ) |
| First Posted: | March 1, 2021 Key Record Dates |
| Last Update Posted: | February 24, 2022 |
| Last Verified: | February 2022 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared. |
| Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) |
| Time Frame: | AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. |
| Access Criteria: | When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. |
| URL: | https://astrazenecagroup-dt.pharmacm.com/DT/Home |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by AstraZeneca:
|
Chemotherapy Aggressive malignancy Programmed cell death ligand-1 Platinum-based chemotherapy |
Additional relevant MeSH terms:
|
Lung Neoplasms Small Cell Lung Carcinoma Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms |
Carboplatin Etoposide Durvalumab Antineoplastic Agents Antineoplastic Agents, Phytogenic Topoisomerase II Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents, Immunological |